Human biodistribution and dosimetry of [18F]nifene, an α4β2* nicotinic acetylcholine receptor PET tracer
The α4β2* nicotinic acetylcholine receptor (nAChR) system is implicated in many neuropsychiatric pathologies. [18F]Nifene is a positron emission tomography (PET) ligand that has shown promise for in vivo imaging of the α4β2* nAChR system in preclinical models and humans. This work establishes the ra diation burden associated with [18F]nifene PET scans in humans. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - August 17, 2017 Category: Nuclear Medicine Authors: Tobey J. Betthauser, Ansel T. Hillmer, Patrick J. Lao, Emily Ehlerding, Jogeshwar Mukherjee, Charles K. Stone, Bradley T. Christian Source Type: research
[11C]PF-3274167 as a PET radiotracer of oxytocin receptors: radiosynthesis and evaluation in rat brain
Oxytocin plays a major role in the regulation of social interactions in mammals by interacting with the oxytocin receptor (OTR) expressed in the brain. Furthermore, the oxytocin system appears as a possible therapeutic target in autism spectrum disorders and other psychiatric troubles, justifying current pharmacological researches. Since no specific PET radioligand is currently available to image OTR in the brain, the aim of this study was to radiolabel the specific OTR antagonist PF-3274167 and to evaluate [11C]PF-3274167 as a potential PET tracer for OTR in rat brains. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - August 2, 2017 Category: Nuclear Medicine Authors: Benjamin Vidal, Iuliia A. Karpenko, Fran çois Liger, Sylvain Fieux, Caroline Bouillot, Thierry Billard, Marcel Hibert, Luc Zimmer Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 20, 2017 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 20, 2017 Category: Nuclear Medicine Source Type: research
[11C]AZ10419096 – a full antagonist PET radioligand for imaging brain 5-HT1B receptors
The serotonergic system is widely present in all regions of the central nervous system (CNS) and plays a key modulatory role in many of its functions. Positron emission tomography (PET) is used to study several serotonin receptors in CNS in vivo. The G-protein coupled receptor 5-HT1B is mostly present in the occipital cortex and in midbrain and is linked to several psychiatric disorders. There is evidence that agonist PET radioligands for neuroreceptors are more sensitive to endogenous neurotransmitters than antagonists. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 20, 2017 Category: Nuclear Medicine Authors: Anton Lindberg, Sangram Nag, Magnus Schou, Akihiro Takano, Junya Matsumoto, Nahid Amini, Charles S. Elmore, Lars Farde, Victor W. Pike, Christer Halldin Source Type: research
[11C]AZ10419096 - a full antagonist PET radioligand for imaging brain 5-HT1B receptors
The serotonergic system is widely present in all regions of the central nervous system (CNS) and plays a key modulatory role in many of its functions. Positron emission tomography (PET) is used to study several serotonin receptors in CNS in vivo. The G-protein coupled receptor 5-HT1B is mostly present in the occipital cortex and in midbrain and is linked to several psychiatric disorders. There is evidence that agonist PET radioligands for neuroreceptors are more sensitive to endogenous neurotransmitters than antagonists. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 20, 2017 Category: Nuclear Medicine Authors: Anton Lindberg, Sangram Nag, Magnus Schou, Akihiro Takano, Junya Matsumoto, Nahid Amini, Charles S. Elmore, Lars Farde, Victor W. Pike, Christer Halldin Source Type: research
Continuation of Comprehensive Quality Control of the itG 68Ge/68Ga Generator and Production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Research Studies
Performance of a second itG 68Ge/68Ga generator system and production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC were tested over one year as an accompaniment to a previously published study (J Nucl Med. 2016;57:1402-1405). (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 13, 2017 Category: Nuclear Medicine Authors: Alejandro Amor-Coarasa, James M. Kelly, Monika Gruca, Anastasia Nikolopoulou, Shankar Vallabhajosula, John W. Babich Source Type: research
18F-Labeled perfluorocarbon droplets for positron emission tomography imaging
Nanoscale perfluorocarbon (PFC) droplets have been used to create imaging agents and drug delivery vehicles. However, development and characterization of new formulations of PFC droplets are hindered because of the lack of simple methods for quantitative and sensitive assessment of whole body tissue distribution and pharmacokinetics of the droplets. To address this issue, a general-purpose method for radiolabeling the inner core of nanoscale perfluorocarbon droplets with a hydrophobic and lipophobic fluorine-18 compound was developed, so that positron emission tomography (PET) and quantitative biodistribution studies can b...
Source: Nuclear Medicine and Biology - July 12, 2017 Category: Nuclear Medicine Authors: Nagina Amir, David Green, Jeff Kent, Yun Xiang, Ivan Gorelikov, Minseok Seo, Megan Blacker, Nancy Janzen, Shannon Czorny, John F. Valliant, Naomi Matsuura Source Type: research
Synthesis and evaluation of a 99mTc-labeled chemokine receptor antagonist peptide for imaging of chemokine receptor expressing tumors
The chemokine receptor CXCR4 is highly expressed in tumor cells and plays an important role in tumor metastasis. In the present study, we report on the evaluation of a new radiopharmaceutical peptide for its potential to visualization for CXCR4-expressing tumors in vivo. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2017 Category: Nuclear Medicine Authors: Azadeh Mikaeili, Mostafa Erfani, Omid Sabzevari Source Type: research
Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: development of an optimized conjugation protocol and 177Lu labeling
We have previously developed a pretargeting approach for affibody-mediated cancer therapy based on PNA-PNA hybridization. In this article we have further developed this approach by optimizing the production of the primary agent, ZHER2:342-SR-HP1, and labeling the secondary agent, HP2, with the therapeutic radionuclide 177Lu. We also studied the biodistribution profile of 177Lu-HP2 in mice, and evaluated pretargeting with 177Lu-HP2 in vitro and in vivo. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2017 Category: Nuclear Medicine Authors: Mohamed Altai, Kristina Westerlund, Justin Velletta, Bogdan Mitran, Hadis Honarvar, Amelie Eriksson Karlstr öm Source Type: research
18F-Labelled perfluorocarbon droplets for positron emission tomography imaging
Nanoscale perfluorocarbon (PFC) droplets have been used to create imaging agents and drug delivery vehicles. However, development and characterization of new formulations of PFC droplets are hindered because of the lack of simple methods for quantitative and sensitive assessment of whole body tissue distribution and pharmacokinetics of the droplets. To address this issue, a general-purpose method for radiolabeling the inner core of nanoscale perfluorocarbon droplets with a hydrophobic and lipophobic fluorine-18 compound was developed, so that positron emission tomography (PET) and quantitative biodistribution studies can b...
Source: Nuclear Medicine and Biology - July 12, 2017 Category: Nuclear Medicine Authors: Nagina Amir, David Green, Jeff Kent, Yun Xiang, Ivan Gorelikov, Minseok Seo, Megan Blacker, Nancy Janzen, Shannon Czorny, John F. Valliant, Naomi Matsuura Source Type: research
111In-DTPA-D-Phe −1-Asp0-D-Phe1-octreotide exhibits higher tumor accumulation and lower renal radioactivity than 111In-DTPA-D-Phe1-octreotide
111In-DTPA-D-Phe1-octreotide scintigraphy is an important method of detecting neuroendocrine tumors. We previously reported that a new derivative of 111In-DTPA-D-Phe1-octreotide, 111In-DTPA-D-Phe −1-Asp0-D-Phe1-octreotide, accomplished the reduction of prolonged renal accumulation of radioactivity. The aim of this study was to evaluate the tumor accumulation of 111In-DTPA-D-Phe−1-Asp0-D-Phe1-octreotide in vitro and in vivo by comparing it with 111In-DTPA-D-Phe1-octreotide. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2017 Category: Nuclear Medicine Authors: Nobuhiro Oshima, Hiromichi Akizawa, Hirotake Kitaura, Hidekazu Kawashima, Songji Zhao, Yan Zhao, Ken-ichi Nishijima, Yoji Kitamura, Yasushi Arano, Yuji Kuge, Kazue Ohkura Source Type: research
O-(2-18F-Fluoroethyl)-L-Tyrosine (18F-FET) Uptake in Insulinoma: First Results from a Xenograft Mouse Model and Human
Herein we have evaluated the uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine (18F-FET) in insulinoma in comparison with those of 6-18F-fluoro-3,4-dihydroxy-L-phenylalanine (18F-FDOPA) providing first data from both murine xenograft model and one patient with proved endogenous hyperinsulinemic hypoglycemia. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2017 Category: Nuclear Medicine Authors: Alessio Imperiale, Fr édéric Boisson, Guillaume Kreutter, Bernard Goichot, Izzie Jacques Namer, Philippe Bachellier, Patrice Laquerriere, Laurence Kessler, Patrice Marchand, David Brasse Source Type: research
Comparison of Planar, PET and Well-counter Measurements of Total Tumor Radioactivity in a Mouse Xenograft Model
Quantitative small animal radionuclide imaging studies are often carried out with the intention of estimating the total radioactivity content of various tissues such as the radioactivity content of mouse xenograft tumors exposed to putative diagnostic or therapeutic agents. We show that for at least one specific application, positron projection imaging (PPI) and PET yield comparable estimates of absolute total tumor activity and that both of these estimates are highly correlated with direct well-counting of these same tumors. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 29, 2017 Category: Nuclear Medicine Authors: Michael V. Green, Jurgen Seidel, Mark R. Williams, Karen J. Wong, Anita Ton, Falguni Basuli, Peter L. Choyke, Elaine M. Jagoda Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - June 21, 2017 Category: Nuclear Medicine Source Type: research
